London – September 24, 2026 -- Artemis Growth Partners, a global investment firm specializing in regulated medical cannabis and emergent medicinal therapeutics, has appointed James Hayward as Advisory Director following his 35-year career at JPMorgan.

San Diego – September 24, 2026 -- Viking Therapeutics plans to raise $400 million through simultaneous public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032, with proceeds earmarked for its obesity drug pipeline.

Washington – September 23, 2026 -- Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP), adding a major biopharmaceutical player to a coalition working to resolve coverage and access barriers for rare disease patients.

Los Angeles – September 23, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.

Vancouver and Glil Yam, Israel – September 23, 2026 -- IM Cannabis Corp. (Nasdaq: IMCC) has regained compliance with Nasdaq's minimum bid price rule, closing a deficiency matter that had threatened its listing status on the exchange.

Jacksonville, Florida – September 23, 2026 -- Theragen presented machine-learning findings at the Society for Minimally Invasive Spine Surgery (SMISS) 2026 Annual Forum showing that daily wear time of its ActaStim®-S bone growth stimulator predicts clinically meaningful pain improvement after spinal fusion surgery, with benefits plateauing around 13 hours of daily use.

Toronto – September 23, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has hit its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of its end-of-September guidance, and will now expand recruitment to as many as 150 patients.

Suzhou, China – September 23, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

New Taipei City – September 23, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.

Pune, India – – September 22, 2026 -- The global exosomes market is set to grow nearly tenfold over the next decade, expanding from USD 230.55 million in 2025 to USD 2,250 million by 2034, according to a new analysis from Maximize Market Research. The projected 28.8% compound annual growth rate between 2026 and 2034 places exosome technology among the fastest-expanding segments in biopharmaceutical R&D.